FDA grants orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis

FDA recently cleared United Therapeutics' investigational new drug application for the TETON study to evaluate the use of treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis, and the company expects to commence enrolment in 2021.

Source:

Biospace Inc.